Mental Health Research Accelerator Act of 2025
- Sponsor
- Rep. Thompson, Mike [D-CA-4]
- Committees
- Ways and Means Committee (primary)
- Last action
- Mar 11, 2025
Bottom line
The bill creates a time-limited, capped tax credit to incentivize private and public investment in research for mental health and neurodegenerative disorders, with a focus on public-private partnerships and IP sharing.
What it actually does
This bill establishes a new 25% federal tax credit for expenses incurred in translational research related to neurodegenerative diseases and psychiatric conditions. It sets annual aggregate national limitations on the credit amount, which will be allocated by the Secretary of the Treasury based on scientific merit and other criteria. The credit is transferable by tax-exempt entities to eligible project partners and is set to terminate after December 31, 2035.
Proponents argue
Proponents argue that this bill will accelerate the development of much-needed treatments and cures for devastating neurodegenerative and psychiatric conditions by providing a significant financial incentive for research and development. They emphasize the importance of targeted investment in these areas, which often involve high-risk, long-term research, and highlight the potential for public-private partnerships to leverage diverse expertise and resources.
Opponents contend
Critics might contend that while the goal is laudable, a targeted tax credit with an allocation mechanism could lead to inefficiencies, potential for lobbying influence, and may not be the most effective way to stimulate broad scientific advancement. Some may argue that a more general R&D tax credit or direct funding through agencies like NIH would be more equitable and less susceptible to political interference in scientific funding decisions, or raise concerns about the long-term fiscal impact of new tax expenditures.
The bill is relatively short and its core provisions are understandable, but the technical details of tax credits and inter-agency allocation mechanisms require careful reading.
Section 2(a), new Section 45BB(a)
Translational Research Credit Establishment
This provision creates a new tax credit, the 'translational research credit,' equal to 25% of the expenses paid or incurred by a taxpayer for translational research into neurodegenerative diseases and psychiatric conditions. This credit is designed to incentivize private sector investment in these specific areas of medical research.
Supporters argue
Supporters argue that a direct credit incentivizes critical research that might otherwise be underfunded due to its high risk and long development timelines, ultimately benefiting public health.
Critics contend
Opponents might argue that a 25% credit may not be sufficient to significantly alter research investment decisions, or that it could lead to 'crowding out' other important research areas not covered by the credit.
Tradeoffs
The provision balances the need to incentivize specific research with the cost to federal revenue and the potential for distorting research priorities.
Section 2(b), new Section 45BB(b)
Aggregate National Credit Limitation and Allocation
This section sets annual caps on the total amount of translational research credits that can be claimed nationwide: $1 billion for 2026, $2 billion annually from 2027 through 2030, and $1 billion for 2031. The Secretary of the Treasury, in consultation with health agencies, is tasked with allocating these credits to applicants based on scientific merit, inclusion of all research phases, emphasis on new therapeutics/devices, repurposing existing drugs, and public-private partnerships with IP sharing.
Section 2(c), new Section 45BB(c)
Credit Transferability for Tax-Exempt Entities
This provision allows tax-exempt entities (such as federal, state, tribal, or local governments, and 501(c)(3) organizations) that would otherwise be eligible for the credit to elect to transfer all or a portion of it to an 'eligible project partner.' An eligible project partner is a person identified in the credit application who participates in or funds the research. This mechanism enables tax-exempt research institutions to benefit from the credit even if they do not have a tax liability against which to claim it directly.
Section 2(e), new Section 45BB(e)
Credit Termination Date
This provision establishes a sunset date for the translational research credit, specifying that no credit will be allowed for any taxable year beginning after December 31, 2035. This makes the credit a temporary measure, subject to future review and potential reauthorization by Congress.
The Secretary of the Treasury is required to consult with the Secretary of Health and Human Services, the Administrator of the Food and Drug Administration, and the Director of the National Institutes of Health when prescribing regulations for the credit allocation process.
Section 2(b)(2)(D)
Why it matters:This is standard legislative practice to ensure inter-agency coordination for programs that cross departmental jurisdictions.
Case for: This consultation ensures that the allocation criteria and process are informed by scientific and public health expertise, maximizing the credit's effectiveness in advancing medical research.
Case against: No specific case against consultation is typically made, though some might argue that it adds layers of bureaucracy and potential for differing agency priorities to slow down the regulatory process.
Estimated impact: Ensures scientific and public health expertise guides the allocation of billions in research credits.
The regulations for credit allocation must include standards for public-private partnerships, with priority given to collaborative efforts and sharing of intellectual property held by tax-exempt entities involved in the project.
Section 2(b)(2)(D)(v)
Why it matters:This is a specific policy directive for the Secretary to consider during regulation development, rather than a direct statutory mandate on all applicants.
Case for: Prioritizing IP sharing for tax-exempt entities can promote open science, accelerate the dissemination of research findings, and ensure that publicly supported research benefits the broader public rather than being exclusively privatized.
Case against: Some private sector partners might be less inclined to participate in public-private partnerships if they perceive that their intellectual property interests are not adequately protected or that the IP sharing requirements are too onerous, potentially hindering collaboration.
Estimated impact: Influences the structure and terms of public-private research collaborations, potentially fostering more open innovation models.
Any expenses taken into account for the new translational research credit that are also 'qualified research expenses' under Section 41 (the general R&D credit) shall be taken into account when determining 'base period research expenses' for purposes of applying Section 41 to subsequent taxable years.
Section 2(d)(2)
Why it matters:This is a standard technical provision to prevent double-counting of expenses for current year credits while ensuring that the new credit does not unfairly disadvantage future claims under the existing R&D credit by artificially lowering the base.
Case for: This provision ensures fairness and consistency in how research expenses are treated across different tax credits, preventing unintended negative consequences for companies that might utilize both incentives over time.
Case against: No specific case against this technical coordination rule is typically made, as it is designed to prevent unintended penalties for taxpayers.
Estimated impact: Ensures long-term consistency in R&D tax credit calculations for companies utilizing both credits, potentially saving them significant administrative and financial burdens.